Alimera Sciences Inc (NASDAQ:ALIM), headquartered in Georgia, Atlanta have raised $72.1 million through the sale of 6.6 million shares. The specialist ophthalmics company possesses a lead compound, “Iluvien” for the treatment of diabetic macular edema. The Iluvien product is a new intravitreal insert (3.5mm in length X 0.37mm in diameter) that may be surgically inserted with a 25 gauge needle after which it slowly releases a very low dose corticosteroid fluocinoclone acetonide directly into the vitreous for up to three years.
Diabetic macular edema company raises $72 million on NASDAQ
- by swdadmin